Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
2026-09-29 21:30
•Prosper Junior Bakiny •The Motley Fool
•••• •• Axe Cap view
Why Eli Lilly’s Stock Stayed Firm Despite Viking’s Weight-Loss Drug Win
Viking Therapeutics impressed with new trial data, yet Eli Lilly’s share price barely budged.
Viking Therapeutics just reported strong clinical results for its weight-loss drug VK2735, showing significant body weight reduction and promising maintenance data. That should be good news for anyone watching this fast-growing market. Yet Eli Lilly, the current leader with its own successful drug Zepbound and advanced pipeline candidates, barely flinched. Why? Lilly’s weight-loss therapy doesn’t just rely on initial results; it has smart dose-reduction strategies and promising next-gen medicines like retatrutide that investors trust more. Viking still needs bigger Phase 3 trials to prove itself, making it a higher risk bet. For South African investors, this dynamic keeps USD/ZAR relevant—dollar strength or weakness will impact the import cost and pricing of these drugs locally and shape pharma sector sentiment. Keep an eye on companies like Aspen or Adcock Ingram if local pharma exposure is your goal. This story may flip if Viking nails Phase 3 results first or Lilly stumbles on pipeline setbacks, but for now, Lilly’s established position holds firm. this is just our opinion and not financial advice
We’d watch Viking closely but avoid buying now given early stage risk. Hold or selectively add Eli Lilly for exposure to the weight-loss theme, while tracking USD/ZAR for currency impacts on SA pharma imports.
- LLY
- VKTX
- USD/ZAR
- VKTX fails to replicate Phase 2 success in Phase 3 trials
- Eli Lilly faces pipeline or regulatory setbacks affecting its weight-loss portfolio
6/10
Viking Therapeutics released impressive clinical trial results for its weight-loss drug VK2735, showing 16-19% body weight loss and strong maintenance results. However, Eli Lilly's stock barely moved because the company has its own robust maintenance strategies (Foundayo and dose reduction approaches) and a deeper pipeline. While Viking could become a competitor in the growing weight-loss market, it still needs to confirm results in larger Phase 3 trials, and Eli Lilly remains the safer, more established choice.
Our take is based on reporting first published by The Motley Fool.